SCHEDULE: Wellington Management Discloses 5.3% Stake in Akero Therapeutics

Wellington Management Group LLP and its affiliates have reported a 5.3% beneficial ownership stake in Akero Therapeutics, Inc. common stock as of September 30, 2025.

Summary

• Wellington Management Group LLP, along with its affiliated entities Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, has filed a Schedule 13G.
• The filing reports beneficial ownership of Akero Therapeutics, Inc. common stock (CUSIP: 00973Y108).
• As of September 30, 2025, Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively beneficially own 4,251,861 shares, representing 5.3% of the class.
• Wellington Management Company LLP, a subsidiary, beneficially owns 4,251,861 shares, representing 5.0% of the class.
• The reporting persons hold the shares with shared voting power of 3,746,574 shares (for the group) and 3,717,248 shares (for Wellington Management Company LLP).
• Shared dispositive power is 4,251,861 shares (for the group) and 4,026,115 shares (for Wellington Management Company LLP).
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Akero Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a major institutional investor like Wellington Management is generally viewed positively, as it suggests confidence in the issuer's value, even if it's a passive investment.

Positives

• A significant institutional investor, Wellington Management, has taken a substantial passive stake (5.3%) in Akero Therapeutics, indicating potential confidence in the company's long-term prospects.

Negatives

• The filing itself does not contain any negative information regarding Akero Therapeutics.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in the biotechnology or pharmaceutical sector, specifically in companies like Akero Therapeutics. Large passive stakes by reputable asset managers like Wellington Management can signal market validation for a company within its industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase confidence among existing shareholders and attract new investors, potentially influencing stock price positively.

Key Dates

Keywords

Akero Therapeutics, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, AKRO